FDA warns Novo Nordisk over unreported potential Ozempic side effects
Novo Nordisk, the pharmaceutical company behind Ozempic, has received a warning letter from the U.S. Food and Drug…
The era of $199 copycat weight loss drugs is ending — and it could cost patients
After two splashy Super Bowl commercials focused on making weight loss medication more accessible, Hims & Hers will…
Weight-loss drug pioneer announces €432m investment to build pill plant in Athlone – The Irish Times
Weight-loss drug pioneer Novo Nordisk will invest €432 million in upgrading its Athlone plant to produce the tablet…
The weight-loss drug revolution looks like a winner for Ireland’s economy – The Irish Times
Smartphone sales eclipsed PC sales in 2011, making the smartphone the primary computing platform on the planet. Officials…
Ozempic, Wegovy list prices to be slashed by up to 50%
Weight loss drugmaker Novo Nordisk will cut the list prices of Ozempic and Wegovy by up to 50%…
1 Reason Why I’d Hold This Weight‑Loss Drug Leader Through Any Market Crash
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are locked in a battle around GLP-1 weight-loss drugs.…
Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access
New, lower list price of $675 per month across Wegovy®, Ozempic®, and Rybelsus®, effective January 1, 2027, addresses…
NHS must keep medicine rebate down or lose investment
Wednesday 18 February 2026 2:27 pm | Updated: Wednesday 18 February 2026 3:10 pm Share Facebook Share on Facebook…
Dr Reddy’s says Wegovy copycat to be priced competitively, with 50-60pc discounts feasible
HYDERABAD, Feb 18 — Indian drugmaker Dr Reddy’s Laboratories hopes to launch a generic version of Novo Nordisk’s…
Novo Nordisk set to make Wegovy pill in Ireland for markets outside US – The Irish Times
Wight loss drug company Novo Nordisk will expand its facility in Athlone, chief executive Mike Doustdar says. The…
What’s the Better Long-Term Investment?
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are rivals in the GLP-1 drug market and are…
The most controversial Super Bowl ad of 2025 is back for more
Super Bowl Sunday is the holy grail of advertising thanks to its massive viewership, with an average of…